OSOded Shamriz

Oded Shamriz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Oded Shamriz has a total of 171 co-authors. Here are the top co-authors by number of shared publications:

  • Aviv Talmon

    Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

    11 shared publications
  • Yaarit Ribak

    Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

    11 shared publications
  • Limor Rubin

    Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

    10 shared publications
  • Yuval Tal

    Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Medical Organization, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

    10 shared publications
  • Yuval Tal

    Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem

    8 shared publications
  • Atar Lev

    Pediatric Department A and Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Ramat-Gan, Israel

    7 shared publications

Latest Publications

  • Open Access

    Severe eosinophilia and risk of major disease and mortality: A nationwide cohort study of children and adults

    by Shay Nemet, Daniel Elbirt, Ramon Cohen, Keren Mahlab-Guri, Vered Shkalim Zemer, Ilan Asher, Aviv Talmon, Limor Rubin, Yaarit Ribak, Eyal Ben-Dori, et al.

  • Open Access

    NDUFS4, a mitochondrial complex I subunit, is essential for T-cell metabolic fitness and immune function

    by Oded Shamriz, Zahala Bar-On, Omri Yosef, Leonor Cohen-Daniel, Ayelet Sheer, Or Reuven, Wajeeh Salaymeh, Amijai Saragovi, Raz Somech, Atar Lev, et al.

    Introduction: Mitochondrial metabolism is essential for T-cell function, but the roles of individual electron transport chain (ETC) components are unclear. Here, we aimed to explore the role of mitochondrial complex I (CI) subunit NADH:ubiquinone oxidoreductase iron-sulfur protein 4 (NDUFS4) in T-cell metabolic fitness and immunity. Methods: We used a T cell-specific Ndufs4 knockout mouse model to find that NDUFS4 deficiency disrupts CI function, leading to metabolic and redox imbalances. Additionally, T cells from a patient with Leigh syndrome induced by NDUFS4 loss-of-function were analyzed. Results: Ndufs4-deficient T cells exhibit impaired OXPHOS, reduced respiratory capacity, and increased glycolysis, accompanied by reactive oxygen species (ROS) accumulation and defective TCR-driven activation, including reduced proliferation and cytokine production. In vivo, Ndufs4(-/-) mice show T-cell lymphopenia and impaired humoral and cytotoxic immunity. Importantly, T cells from a single Leigh syndrome patient with an NDUFS4 loss-of-function variant showed similar defects, including impaired activation and proliferation. Discussion: These findings highlight the importance of NDUFS4 for human immunity and establish a mechanistic link between complex I dysfunction and T-cell immunodeficiency. Our results identify NDUFS4 as a key regulator connecting mitochondrial integrity to adaptive immune function.


  • Open Access

    IVIG-associated anterior uveitis resolving after switch to subcutaneous immunoglobulin

    by Vered Schichter Konfino, Oded Shamriz

    Introduction: Intravenous immunoglobulin (IVIG) therapy can occasionally induce unexpected inflammatory complications. Materials and methods: A case report and literature review. Results: We report a patient with hypogammaglobulinemia and systemic autoimmunity who developed reproducible unilateral anterior uveitis following IVIG administration across multiple formulations. Discontinuation of IVIG resolved the ocular inflammation but caused underlying disease exacerbation. Transition to facilitated subcutaneous immunoglobulin (SCIG) achieved stable serum IgG levels and maintained complete ocular and systemic remission over a four-year follow-up period. Conclusion: This case demonstrates peak-driven immune activation as a plausible mechanism for IVIG-induced uveitis and highlights SCIG as a safe, effective therapeutic alternative that bypasses rapid peak IgG dynamics while preserving immune protection.


  • Open Access

    β-Actin Deficiency in Baraitser-Winter Syndrome Type 1 Disrupts T-Cell Function and Immune Regulation: Implications for Targeted Therapy in Actinopathies

    by Zahala Bar-On, Or Reuven, Atar Lev, Amos J. Simon, Wajeeh Salaymeh, Alit Shalom, Raz Somech, Ortal Barel, Sigal Porges, Elisheva Javasky, et al.

    Purpose: Baraitser-Winter syndrome type 1 (BRWS1) is a rare disorder characterized by intellectual disability, short stature, facial dysmorphism, cortical malformations, macrothrombocytopenia, and recurrent infections. BRWS1 is caused by loss-of-function variants in ACTB , leading to β-actin deficiency. Given the essential role of the actin cytoskeleton in T-cell activation, the immunological consequences of ACTB mutations remain unexplored. Here, we characterize immune dysfunction associated with a novel ACTB variant in a patient with BRWS1. Methods: Whole-exome sequencing identified a heterozygous ACTB p.Gln360ProfsTer4 variant in a patient with BRWS1 and combined immunodeficiency. Functional studies were performed in HEK293T cells transfected with wild-type and mutant ACTB constructs. Patient-derived T cells were analyzed for immunological synapse formation, cytokine production, activation, and proliferation. The therapeutic effects of exogenous IL-2 and dupilumab were evaluated. Results: The mutant β-actin protein was rapidly degraded and exerted a dominant-negative effect on wild-type β-actin, thereby disrupting cytoskeletal integrity. Patient-derived T cells demonstrated defective immunological synapse formation, reduced intra-synaptic IL-2 levels, and impaired activation and proliferation. Supplementation with exogenous IL-2 partially restored T-cell function in vitro. Notably, dupilumab treatment led to significant clinical and immunological improvement, suggesting a role in restoring immune regulation. Conclusion: BRWS1 represents a novel primary immune regulatory disorder. Our findings highlight actinopathy-driven immunodeficiency as a target for therapeutic intervention, with broader implications for cytoskeletal disorders.


  • Clonal relationship between juvenile xanthogranuloma and juvenile myelomonocytic leukaemia: insights from a PTPN11 missense variant

    by Inbar Kobal, Vered Molho-Pessach, Sigal Matza-Porges, Stephanie Benshushan, Oded Shamriz, Eve Finkelstein

    Juvenile xanthogranuloma (JXG) is typically a benign non-Langerhans cell histiocytosis, but it has been rarely associated with juvenile myelomonocytic leukaemia (JMML). Mutations in the RAS–MAPK (mitogen-activated protein kinase) pathway are implicated in both conditions, suggesting a shared genetic basis. However, only one prior case has demonstrated a clonal relationship. We report the case of a 21-month-old boy with a progressive yellow papulonodular rash, dusky plaques and recurrent infections. Skin biopsy confirmed JXG, and exome sequencing revealed a somatic PTPN11 (c.226G>A) variant in both peripheral blood (32.6%) and skin lesions (27.2%). The early identification of this mutation prompted urgent haemato-oncological evaluation. Two weeks later, the patient developed overt JMML and was successfully treated with chemotherapy and bone marrow transplantation. The shared mutation supports a clonal relationship between JXG and JMML. This case highlights the value of early genetic testing in atypical JXG and represents the second documented case of clonally related, sequential JXG and JMML.


  • Open Access

    Case Report: Clinical manifestations of uncommon monogenic disorders: revisiting activated phosphoinositide 3-kinase delta syndrome 2

    by Oded Shamriz, Amarilla Mandola, Amos J. Simon, Atar Lev, Pierre Attal, Chen Nadler, Ortal Barel, Yulia Khavkin, Rachel Eisenberg, Raz Somech, et al.

    Aim: Pediatricians are trained to identify recurrent or unusual infections in children, prompting evaluation for inborn errors of immunity (IEI). Some monogenic IEI, however, may present atypically. This study describes our experience with children diagnosed with activated phosphoinositide 3-kinase delta syndrome (APDS2) including unusual presentations.Methods: A retrospective review was conducted on two children diagnosed with APDS2 at Shaare Zedek and Sheba Tel-Hashomer Medical Centers in Israel. Both patients underwent immune assessments, genetic testing, and treatment between 2019 and 2024.Results: Two patients, a 17-year-old female (P1) and a 7-year-old male (P2), were diagnosed with APDS2 after presenting with recurrent juvenile parotitis (P1) and severe lymphadenopathy (P2). Immunologic evaluation revealed hypogammaglobulinemia and combined immune deficiency. Genetic testing identified PIK3R1 variants (c.1425 + 1G > T in P1 and c.1425 + 1G > C in P2). Both received intravenous immunoglobulins and prophylactic antibiotics. P2 was treated with rapamycin, leading to resolution of lymphadenopathy.Conclusion: This report highlights the clinical presentation of APDS2, a rare monogenic IEI in children, including the atypical manifestation of RJP and the common feature of lymphadenopathy. Pediatricians should stay vigilant for red flags of IEI during clinical evaluations, as early diagnosis and multidisciplinary care are crucial for effective management.


  • IgE deficiency (<2.5 IU / mL ) in children: Clinical insights from a population‐based study of 123,393 subjects

    by Shay Nemet, Daniel Elbirt, Ramon Cohen, Keren Mahlab‐Guri, Shira Bezalel‐Rosenberg, Ilan Asher, Limor Rubin, Aviv Talmon, Yaarit Ribak, Ruslan Sergienko, et al.

    Background: Immunoglobulin (Ig)E deficiency (N = 5574; 57.01%) and lowest in the normal IgE group ( N = 24,171; 38.91%). The IgE‐deficient group fell in the middle range ( N = 903; 42.72%). In IgE‐deficient children, allergic rhinitis was less common (11.26% vs. 14.09%). Conclusion: IgE deficiency in children is associated with higher risks of solid tumors, autoimmune disorders, and IEI, suggesting potential immune dysregulation. Close monitoring of IgE‐deficient children should be considered.


  • Open Access

    Dual biological treatments in immune-mediated disorders: a single center experience

    by Oded Shamriz, Elchanan Parnasa, Limor Rubin, Aviv Talmon, Yaarit Ribak, Isaam Hindi, Hagit Peleg, Ronit Confino-Cohen, Yuval Tal

    Physicians may encounter situations where they need to co-administer omalizumab with non–IgE-targeting monoclonal antibodies. In this study, we share our experience with these dual biologic treatments. To evaluate the efficacy and safety of dual biological therapy using omalizumab and non-IgE-targeting monoclonal antibodies at a single center. We retrospectively reviewed the medical records of adults treated with a dual biological therapy regimen consisting of omalizumab and another biologic between 2020 and 2022. Our review identified nine patients (age range: 51–75 years, 7 women and 2 men) who were treated with omalizumab for high Th2 disorders, including chronic spontaneous urticaria (n = 7) and asthma (n = 2). Seven patients received a second biologic for co-existing non-Th2 disorders, while two received an additional biologic to better control their Th2-mediated disorders. The patients were treated with the following biologics: anti-IL-5 agents (mepolizumab [n = 1] and benralizumab [n = 1]), the IL-4/13 inhibitor dupilumab (n = 1), the anti-IL-17 biologic secukinumab (n = 1), the IL-1 inhibitor anakinra (n = 1), the anti-calcitonin gene–related peptide agent fremanezumab (n = 1), and anti-TNF-α agents (etanercept [n = 1], golimumab [n = 1], and adalimumab [n = 1]). Dual biotherapy was administered for 3–34 months with observed clinical improvement. No adverse events or infections were reported. Dual biological treatment with omalizumab and another biologic appears to be safe, with no need to discontinue non–IgE-targeting agents during omalizumab therapy.


  • Inflammatory arthritis as an atypical manifestation of Coffin-Siris syndrome linked to a novel ARID1B variant

    by Sigal Matza-Porges, Zahala Bar-On, Atar Lev, Amos J. Simon, Hagit Peleg, Oded Shamriz

    Letters to the Editor; Authors: S. Matza-Porges, Z. Bar-On, A. Lev, A.J. Simon, H. Peleg, O. Shamriz